Research progress of CAR-T cells in the treatment of malignant tumors
CAR-T细胞治疗恶性肿瘤研究进展

摘要

从近些年的临床经验来看，基于CAR（嵌合抗原受体）为基础的细胞免疫属于恶性肿瘤临床治疗的全新研究方向，其特征在于可以借助基因修饰特征获得携带识别肿瘤抗原特异性受体T细胞的功能，同时还能够赋予T细胞靶向杀伤活性功能，达到个性化的治疗。和传统T细胞免疫治疗方式相比，CAR可以借助增进共刺激分子的信号实现对T细胞的强烈杀伤性作用，从而有效应对肿瘤具备免疫抑制为环境以及宿主免疫耐受功能。伴随着转化医学的持续深入研究，对于CAR-T（嵌合抗原受体T细胞免疫治疗法）的免疫性治疗研究也在不断深入，这也为恶性肿瘤的临床治疗提供了全新方向。对此，本文简要分析CAR-T细胞治疗恶性肿瘤的研究进展。

Abstract

From the clinical experience in recent years, cellular immunity based on CAR (chimeric antigen receptor) belongs to a new research direction in the clinical treatment of malignant tumors, which is characterized by the ability to obtain the function of carrying and recognizing tumor antigen specific receptor T cells with the help of gene modification features, and at the same time, the ability to endow T cells with targeted killing activity to achieve personalized treatment. Compared with traditional T cell immunotherapy, CAR can achieve a strong killing effect on T cells by enhancing the signal of costimulatory molecules, so as to effectively cope with tumor with immunosuppressive environment and host immune tolerance. With the continuous in-depth research of translational medicine, the immunotherapy research of CAR-T (chimeric antigen receptor T cell immunotherapy) is also deepening, which also provides a new direction for the clinical treatment of malignant tumors. In this paper, we briefly analyze the research progress of CAR-T cells in the treatment of malignant tumors.